Bacterias for Energy - Revision history

AClearwater: /* A brief look at IP development at NanoLogix (formerly known as Infectech) */

2009-08-17T19:03:28Z

A brief look at IP development at NanoLogix (formerly known as Infectech)

← Older revision		Revision as of 19:03, 17 August 2009
Line 36:		Line 36:
	=A brief look at IP development at NanoLogix (formerly known as Infectech)=		=A brief look at IP development at NanoLogix (formerly known as Infectech)=

	Name change information: [[http://www.redorbit.com/news/health/141833/infectech_inc_approves_name_change_to_nanologix_and_enters_hydrogen/index.html]]		2005 Name change information: [[http://www.redorbit.com/news/health/141833/infectech_inc_approves_name_change_to_nanologix_and_enters_hydrogen/index.html]]

	'''Output:'''<br>		'''Output:'''<br>

AClearwater: /* A brief look at IP development at NanoLogix (formerly known as Infectech) */

2009-08-17T19:03:12Z

A brief look at IP development at NanoLogix (formerly known as Infectech)

← Older revision		Revision as of 19:03, 17 August 2009
Line 35:		Line 35:

	=A brief look at IP development at NanoLogix (formerly known as Infectech)=		=A brief look at IP development at NanoLogix (formerly known as Infectech)=

			Name change information: [[http://www.redorbit.com/news/health/141833/infectech_inc_approves_name_change_to_nanologix_and_enters_hydrogen/index.html]]

	'''Output:'''<br>		'''Output:'''<br>

AClearwater: /* A brief look at IP development at NanoLogix (formerly known as Infectech) */

2009-08-17T18:56:49Z

A brief look at IP development at NanoLogix (formerly known as Infectech)

← Older revision		Revision as of 18:56, 17 August 2009
Line 54:		Line 54:
	**the board is used "to help evaluate and target research and development efforts for products"		**the board is used "to help evaluate and target research and development efforts for products"
	**http://www.reuters.com/article/pressRelease/idUS139804+11-May-2009+PRN20090511		**http://www.reuters.com/article/pressRelease/idUS139804+11-May-2009+PRN20090511
			''Narrative''
			*Third Party Verification of Findings "Dr. Paul Hyman of Ohio State University. Dr. Hyman has achieved the identification and bacterial genetic amplification of an important strain of Mycobacteria faster than what is presently in the medical literature." http://www.aegis.com/NEWS/BW/2004/BW040902.html
			**Infectech has developed a diagnostic test kit based on this technology
	''Tools''		''Tools''
	*"NanoLogix, Inc. signed a feasibility study with the Department of Environmental Science and Engineering of Gannon University in Erie, PA to develop a bioreactor which utilizes NanoLogix's patented bacterial culturing methods in order to produce hydrogen inexpensively." http://www.freerepublic.com/focus/f-news/1415820/posts		*"NanoLogix, Inc. signed a feasibility study with the Department of Environmental Science and Engineering of Gannon University in Erie, PA to develop a bioreactor which utilizes NanoLogix's patented bacterial culturing methods in order to produce hydrogen inexpensively." http://www.freerepublic.com/focus/f-news/1415820/posts

AClearwater: /* A brief look at IP development at NanoLogix (formerly known as Infectech) */

2009-08-17T18:50:28Z

A brief look at IP development at NanoLogix (formerly known as Infectech)

← Older revision		Revision as of 18:50, 17 August 2009
Line 46:		Line 46:
	***"a biotechnology company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases" http://www.nutrapharma.com/		***"a biotechnology company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases" http://www.nutrapharma.com/
	***"Nutra Pharma Corp. (OTCBB: NPHC) announced today that it has signed a letter of intent to acquire 100 percent of the capital stock of Infectech Inc.(Pink Sheets: IFEC) in a cash and stock transaction. The acquisition adds a complete line of patented and patent-pending products and applications." http://findarticles.com/p/articles/mi_m0EIN/is_2003_Sept_8/ai_107398671/		***"Nutra Pharma Corp. (OTCBB: NPHC) announced today that it has signed a letter of intent to acquire 100 percent of the capital stock of Infectech Inc.(Pink Sheets: IFEC) in a cash and stock transaction. The acquisition adds a complete line of patented and patent-pending products and applications." http://findarticles.com/p/articles/mi_m0EIN/is_2003_Sept_8/ai_107398671/
	Research"NanoLogix originally developed the patented intellectual property incorporated as a basis for *Nutra Pharma's (OTC BB: NPHC.OB) Designer Diagnostic test kits. These test kits are currently marketed for use in early detection of infectious human diseases such as tuberculosis and nontuberculosis mycobacterium." http://www.tecnica.com/		*Research"NanoLogix originally developed the patented intellectual property incorporated as a basis for Nutra Pharma's (OTC BB: NPHC.OB) Designer Diagnostic test kits. These test kits are currently marketed for use in early detection of infectious human diseases such as tuberculosis and nontuberculosis mycobacterium." http://www.tecnica.com/
	*"NanoLogix has ascertained through its patent counsel that there are eleven relevant U.S. patents concerning the database containing the terms "Clostridia" and "Hydrogen Production." NanoLogix presently owns five of these eleven issued patents. http://www.freerepublic.com/focus/f-news/1415820/posts see also: Company Press Release: NanoLogix Provides Operations Update and Notification of Shareholder Meeting (http://www.marketwire.com/press-release/Nanologix-Incorporated-1022717.html)		*"NanoLogix has ascertained through its patent counsel that there are eleven relevant U.S. patents concerning the database containing the terms "Clostridia" and "Hydrogen Production." NanoLogix presently owns five of these eleven issued patents. http://www.freerepublic.com/focus/f-news/1415820/posts see also: Company Press Release: NanoLogix Provides Operations Update and Notification of Shareholder Meeting (http://www.marketwire.com/press-release/Nanologix-Incorporated-1022717.html)

AClearwater: /* A brief look at IP development at NanoLogix (formerly known as Infectech) */

2009-08-17T18:46:51Z

A brief look at IP development at NanoLogix (formerly known as Infectech)

← Older revision		Revision as of 18:46, 17 August 2009
Line 45:		Line 45:
	**Nutra Pharma Corp is a biotechnology intellectual property holding company [[http://www.nutrapharma.com/]]		**Nutra Pharma Corp is a biotechnology intellectual property holding company [[http://www.nutrapharma.com/]]
	***"a biotechnology company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases" http://www.nutrapharma.com/		***"a biotechnology company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases" http://www.nutrapharma.com/
			***"Nutra Pharma Corp. (OTCBB: NPHC) announced today that it has signed a letter of intent to acquire 100 percent of the capital stock of Infectech Inc.(Pink Sheets: IFEC) in a cash and stock transaction. The acquisition adds a complete line of patented and patent-pending products and applications." http://findarticles.com/p/articles/mi_m0EIN/is_2003_Sept_8/ai_107398671/
	Research"NanoLogix originally developed the patented intellectual property incorporated as a basis for *Nutra Pharma's (OTC BB: NPHC.OB) Designer Diagnostic test kits. These test kits are currently marketed for use in early detection of infectious human diseases such as tuberculosis and nontuberculosis mycobacterium." http://www.tecnica.com/		Research"NanoLogix originally developed the patented intellectual property incorporated as a basis for *Nutra Pharma's (OTC BB: NPHC.OB) Designer Diagnostic test kits. These test kits are currently marketed for use in early detection of infectious human diseases such as tuberculosis and nontuberculosis mycobacterium." http://www.tecnica.com/
	*"NanoLogix has ascertained through its patent counsel that there are eleven relevant U.S. patents concerning the database containing the terms "Clostridia" and "Hydrogen Production." NanoLogix presently owns five of these eleven issued patents. http://www.freerepublic.com/focus/f-news/1415820/posts see also: Company Press Release: NanoLogix Provides Operations Update and Notification of Shareholder Meeting (http://www.marketwire.com/press-release/Nanologix-Incorporated-1022717.html)		*"NanoLogix has ascertained through its patent counsel that there are eleven relevant U.S. patents concerning the database containing the terms "Clostridia" and "Hydrogen Production." NanoLogix presently owns five of these eleven issued patents. http://www.freerepublic.com/focus/f-news/1415820/posts see also: Company Press Release: NanoLogix Provides Operations Update and Notification of Shareholder Meeting (http://www.marketwire.com/press-release/Nanologix-Incorporated-1022717.html)

AClearwater: /* A brief look at IP development at NanoLogix (formerly known as Infectech) */

2009-08-17T18:43:50Z

A brief look at IP development at NanoLogix (formerly known as Infectech)

← Older revision		Revision as of 18:43, 17 August 2009
Line 43:		Line 43:
	''Data''		''Data''
	*"NanoLogix has assigned the rights to 11 patents and licensed the rights to 18 others to Nutra Pharma for use in diagnostic test kit development. NanoLogix retains a license for the nanotechnology aspects of the assigned patents and the rights to all nanotechnology aspects of the licensed patents. In exchange for this licensing and assignment, Nanologix receives the greater of either a 6% royalty on gross sales or a significant annual guarantee. Revenue has started from this arrangement." http://www.tecnica.com/		*"NanoLogix has assigned the rights to 11 patents and licensed the rights to 18 others to Nutra Pharma for use in diagnostic test kit development. NanoLogix retains a license for the nanotechnology aspects of the assigned patents and the rights to all nanotechnology aspects of the licensed patents. In exchange for this licensing and assignment, Nanologix receives the greater of either a 6% royalty on gross sales or a significant annual guarantee. Revenue has started from this arrangement." http://www.tecnica.com/
	**Nutra Pharma Corp is a biotechnology intellectual property holding company http://www.nutrapharma.com/		**Nutra Pharma Corp is a biotechnology intellectual property holding company [[http://www.nutrapharma.com/]]
			***"a biotechnology company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases" http://www.nutrapharma.com/
	Research"NanoLogix originally developed the patented intellectual property incorporated as a basis for *Nutra Pharma's (OTC BB: NPHC.OB) Designer Diagnostic test kits. These test kits are currently marketed for use in early detection of infectious human diseases such as tuberculosis and nontuberculosis mycobacterium." http://www.tecnica.com/		Research"NanoLogix originally developed the patented intellectual property incorporated as a basis for *Nutra Pharma's (OTC BB: NPHC.OB) Designer Diagnostic test kits. These test kits are currently marketed for use in early detection of infectious human diseases such as tuberculosis and nontuberculosis mycobacterium." http://www.tecnica.com/
	*"NanoLogix has ascertained through its patent counsel that there are eleven relevant U.S. patents concerning the database containing the terms "Clostridia" and "Hydrogen Production." NanoLogix presently owns five of these eleven issued patents. http://www.freerepublic.com/focus/f-news/1415820/posts see also: Company Press Release: NanoLogix Provides Operations Update and Notification of Shareholder Meeting (http://www.marketwire.com/press-release/Nanologix-Incorporated-1022717.html)		*"NanoLogix has ascertained through its patent counsel that there are eleven relevant U.S. patents concerning the database containing the terms "Clostridia" and "Hydrogen Production." NanoLogix presently owns five of these eleven issued patents. http://www.freerepublic.com/focus/f-news/1415820/posts see also: Company Press Release: NanoLogix Provides Operations Update and Notification of Shareholder Meeting (http://www.marketwire.com/press-release/Nanologix-Incorporated-1022717.html)

AClearwater: /* A brief look at IP development at NanoLogix (formerly known as Infectech) */

2009-08-17T18:42:03Z

A brief look at IP development at NanoLogix (formerly known as Infectech)

← Older revision		Revision as of 18:42, 17 August 2009
Line 43:		Line 43:
	''Data''		''Data''
	*"NanoLogix has assigned the rights to 11 patents and licensed the rights to 18 others to Nutra Pharma for use in diagnostic test kit development. NanoLogix retains a license for the nanotechnology aspects of the assigned patents and the rights to all nanotechnology aspects of the licensed patents. In exchange for this licensing and assignment, Nanologix receives the greater of either a 6% royalty on gross sales or a significant annual guarantee. Revenue has started from this arrangement." http://www.tecnica.com/		*"NanoLogix has assigned the rights to 11 patents and licensed the rights to 18 others to Nutra Pharma for use in diagnostic test kit development. NanoLogix retains a license for the nanotechnology aspects of the assigned patents and the rights to all nanotechnology aspects of the licensed patents. In exchange for this licensing and assignment, Nanologix receives the greater of either a 6% royalty on gross sales or a significant annual guarantee. Revenue has started from this arrangement." http://www.tecnica.com/
	**Nutra Pharma Corp is a biotechnology intellectual property holding company		**Nutra Pharma Corp is a biotechnology intellectual property holding company http://www.nutrapharma.com/
	Research"NanoLogix originally developed the patented intellectual property incorporated as a basis for *Nutra Pharma's (OTC BB: NPHC.OB) Designer Diagnostic test kits. These test kits are currently marketed for use in early detection of infectious human diseases such as tuberculosis and nontuberculosis mycobacterium." http://www.tecnica.com/		Research"NanoLogix originally developed the patented intellectual property incorporated as a basis for *Nutra Pharma's (OTC BB: NPHC.OB) Designer Diagnostic test kits. These test kits are currently marketed for use in early detection of infectious human diseases such as tuberculosis and nontuberculosis mycobacterium." http://www.tecnica.com/
	*"NanoLogix has ascertained through its patent counsel that there are eleven relevant U.S. patents concerning the database containing the terms "Clostridia" and "Hydrogen Production." NanoLogix presently owns five of these eleven issued patents. http://www.freerepublic.com/focus/f-news/1415820/posts see also: Company Press Release: NanoLogix Provides Operations Update and Notification of Shareholder Meeting (http://www.marketwire.com/press-release/Nanologix-Incorporated-1022717.html)		*"NanoLogix has ascertained through its patent counsel that there are eleven relevant U.S. patents concerning the database containing the terms "Clostridia" and "Hydrogen Production." NanoLogix presently owns five of these eleven issued patents. http://www.freerepublic.com/focus/f-news/1415820/posts see also: Company Press Release: NanoLogix Provides Operations Update and Notification of Shareholder Meeting (http://www.marketwire.com/press-release/Nanologix-Incorporated-1022717.html)

AClearwater: /* A brief look at IP development at NanoLogix (formerly known as Infectech) */

2009-08-17T18:36:58Z

A brief look at IP development at NanoLogix (formerly known as Infectech)

← Older revision		Revision as of 18:36, 17 August 2009
Line 43:		Line 43:
	''Data''		''Data''
	*"NanoLogix has assigned the rights to 11 patents and licensed the rights to 18 others to Nutra Pharma for use in diagnostic test kit development. NanoLogix retains a license for the nanotechnology aspects of the assigned patents and the rights to all nanotechnology aspects of the licensed patents. In exchange for this licensing and assignment, Nanologix receives the greater of either a 6% royalty on gross sales or a significant annual guarantee. Revenue has started from this arrangement." http://www.tecnica.com/		*"NanoLogix has assigned the rights to 11 patents and licensed the rights to 18 others to Nutra Pharma for use in diagnostic test kit development. NanoLogix retains a license for the nanotechnology aspects of the assigned patents and the rights to all nanotechnology aspects of the licensed patents. In exchange for this licensing and assignment, Nanologix receives the greater of either a 6% royalty on gross sales or a significant annual guarantee. Revenue has started from this arrangement." http://www.tecnica.com/
			**Nutra Pharma Corp is a biotechnology intellectual property holding company
	Research"NanoLogix originally developed the patented intellectual property incorporated as a basis for *Nutra Pharma's (OTC BB: NPHC.OB) Designer Diagnostic test kits. These test kits are currently marketed for use in early detection of infectious human diseases such as tuberculosis and nontuberculosis mycobacterium." http://www.tecnica.com/		Research"NanoLogix originally developed the patented intellectual property incorporated as a basis for *Nutra Pharma's (OTC BB: NPHC.OB) Designer Diagnostic test kits. These test kits are currently marketed for use in early detection of infectious human diseases such as tuberculosis and nontuberculosis mycobacterium." http://www.tecnica.com/
	*"NanoLogix has ascertained through its patent counsel that there are eleven relevant U.S. patents concerning the database containing the terms "Clostridia" and "Hydrogen Production." NanoLogix presently owns five of these eleven issued patents. http://www.freerepublic.com/focus/f-news/1415820/posts see also: Company Press Release: NanoLogix Provides Operations Update and Notification of Shareholder Meeting (http://www.marketwire.com/press-release/Nanologix-Incorporated-1022717.html)		*"NanoLogix has ascertained through its patent counsel that there are eleven relevant U.S. patents concerning the database containing the terms "Clostridia" and "Hydrogen Production." NanoLogix presently owns five of these eleven issued patents. http://www.freerepublic.com/focus/f-news/1415820/posts see also: Company Press Release: NanoLogix Provides Operations Update and Notification of Shareholder Meeting (http://www.marketwire.com/press-release/Nanologix-Incorporated-1022717.html)

AClearwater: /* A brief look at IP development at NanoLogix (formerly known as Infectech) */

2009-08-17T18:35:13Z

A brief look at IP development at NanoLogix (formerly known as Infectech)

← Older revision		Revision as of 18:35, 17 August 2009
Line 54:		Line 54:
	*"NanoLogix, Inc. signed a feasibility study with the Department of Environmental Science and Engineering of Gannon University in Erie, PA to develop a bioreactor which utilizes NanoLogix's patented bacterial culturing methods in order to produce hydrogen inexpensively." http://www.freerepublic.com/focus/f-news/1415820/posts		*"NanoLogix, Inc. signed a feasibility study with the Department of Environmental Science and Engineering of Gannon University in Erie, PA to develop a bioreactor which utilizes NanoLogix's patented bacterial culturing methods in order to produce hydrogen inexpensively." http://www.freerepublic.com/focus/f-news/1415820/posts

	Important Similar Research		''Important Similar Research''
	*Stanford University Research: "NanoLogix says it's the first time that the company knows of someone harvesting electricity from microbes and using it on site. While that may be the case, others have been tinkering with exploiting microorganisms for hydrogen. James Swartz at Stanford University has isolated a microbe that uses energy from the sun to split water molecules and create hydrogen. With this technique, raw materials like sugar aren't needed." http://news.cnet.com/8301-10784_3-9780074-7.html?tag=mncol;title		*Stanford University Research: "NanoLogix says it's the first time that the company knows of someone harvesting electricity from microbes and using it on site. While that may be the case, others have been tinkering with exploiting microorganisms for hydrogen. James Swartz at Stanford University has isolated a microbe that uses energy from the sun to split water molecules and create hydrogen. With this technique, raw materials like sugar aren't needed." http://news.cnet.com/8301-10784_3-9780074-7.html?tag=mncol;title
	**Fundamental Applied Biology		**Fundamental Applied Biology
	***"A company called Fundamental Applied Biology has been formed around Swartz's research." (http://www.f-a-b-inc.com/cell-free-company.html)http://news.cnet.com/8301-10784_3-9780074-7.html?tag=mncol;title		***"A company called Fundamental Applied Biology has been formed around Swartz's research." (http://www.f-a-b-inc.com/cell-free-company.html)http://news.cnet.com/8301-10784_3-9780074-7.html?tag=mncol;title
			''
	NanoLogix Patent Policy		NanoLogix Patent Policy''
	*"NanoLogix intends to dominate the patent coverage for a variety of disruptive technologies at a time when the energy and healthcare industries are screaming for change," said David McClelland, President of NanoLogix. "We are seeing confirmation of this by the caliber of companies we are in discussions with who have expressed interest in our technology, in addition to significant progress we are making in our research collaborations," he added." http://www.azonano.com/news.asp?newsID=1006		*"NanoLogix intends to dominate the patent coverage for a variety of disruptive technologies at a time when the energy and healthcare industries are screaming for change," said David McClelland, President of NanoLogix. "We are seeing confirmation of this by the caliber of companies we are in discussions with who have expressed interest in our technology, in addition to significant progress we are making in our research collaborations," he added." http://www.azonano.com/news.asp?newsID=1006
	*Key Patents (?)		*Key Patents (?)

AClearwater: /* A brief look at IP development at NanoLogix (formerly known as Infectech) */

2009-08-17T18:34:13Z

A brief look at IP development at NanoLogix (formerly known as Infectech)

← Older revision		Revision as of 18:34, 17 August 2009
Line 36:		Line 36:
	=A brief look at IP development at NanoLogix (formerly known as Infectech)=		=A brief look at IP development at NanoLogix (formerly known as Infectech)=

	Output:<br>		'''Output:'''<br>
	Tools		''Tools''
	*commercialization of technologies including:		*commercialization of technologies including:
	**the production of bacteria		**the production of bacteria
	**disease testing kits		**disease testing kits
	Data		''Data''
	*"NanoLogix has assigned the rights to 11 patents and licensed the rights to 18 others to Nutra Pharma for use in diagnostic test kit development. NanoLogix retains a license for the nanotechnology aspects of the assigned patents and the rights to all nanotechnology aspects of the licensed patents. In exchange for this licensing and assignment, Nanologix receives the greater of either a 6% royalty on gross sales or a significant annual guarantee. Revenue has started from this arrangement." http://www.tecnica.com/		*"NanoLogix has assigned the rights to 11 patents and licensed the rights to 18 others to Nutra Pharma for use in diagnostic test kit development. NanoLogix retains a license for the nanotechnology aspects of the assigned patents and the rights to all nanotechnology aspects of the licensed patents. In exchange for this licensing and assignment, Nanologix receives the greater of either a 6% royalty on gross sales or a significant annual guarantee. Revenue has started from this arrangement." http://www.tecnica.com/
	Research"NanoLogix originally developed the patented intellectual property incorporated as a basis for *Nutra Pharma's (OTC BB: NPHC.OB) Designer Diagnostic test kits. These test kits are currently marketed for use in early detection of infectious human diseases such as tuberculosis and nontuberculosis mycobacterium." http://www.tecnica.com/		Research"NanoLogix originally developed the patented intellectual property incorporated as a basis for *Nutra Pharma's (OTC BB: NPHC.OB) Designer Diagnostic test kits. These test kits are currently marketed for use in early detection of infectious human diseases such as tuberculosis and nontuberculosis mycobacterium." http://www.tecnica.com/
	*"NanoLogix has ascertained through its patent counsel that there are eleven relevant U.S. patents concerning the database containing the terms "Clostridia" and "Hydrogen Production." NanoLogix presently owns five of these eleven issued patents. http://www.freerepublic.com/focus/f-news/1415820/posts see also: Company Press Release: NanoLogix Provides Operations Update and Notification of Shareholder Meeting (http://www.marketwire.com/press-release/Nanologix-Incorporated-1022717.html)		*"NanoLogix has ascertained through its patent counsel that there are eleven relevant U.S. patents concerning the database containing the terms "Clostridia" and "Hydrogen Production." NanoLogix presently owns five of these eleven issued patents. http://www.freerepublic.com/focus/f-news/1415820/posts see also: Company Press Release: NanoLogix Provides Operations Update and Notification of Shareholder Meeting (http://www.marketwire.com/press-release/Nanologix-Incorporated-1022717.html)

	Input:<br>		'''Input:'''<br>
	Data		''Data''
	*Board: NanoLogix Creates Science Advisory Board		*Board: NanoLogix Creates Science Advisory Board
	**the board is used "to help evaluate and target research and development efforts for products"		**the board is used "to help evaluate and target research and development efforts for products"
	**http://www.reuters.com/article/pressRelease/idUS139804+11-May-2009+PRN20090511		**http://www.reuters.com/article/pressRelease/idUS139804+11-May-2009+PRN20090511
	Tools		''Tools''
	*"NanoLogix, Inc. signed a feasibility study with the Department of Environmental Science and Engineering of Gannon University in Erie, PA to develop a bioreactor which utilizes NanoLogix's patented bacterial culturing methods in order to produce hydrogen inexpensively." http://www.freerepublic.com/focus/f-news/1415820/posts		*"NanoLogix, Inc. signed a feasibility study with the Department of Environmental Science and Engineering of Gannon University in Erie, PA to develop a bioreactor which utilizes NanoLogix's patented bacterial culturing methods in order to produce hydrogen inexpensively." http://www.freerepublic.com/focus/f-news/1415820/posts